Page last updated: 2024-09-03

gefitinib and Dysphagia

gefitinib has been researched along with Dysphagia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K1
Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J1

Trials

1 trial(s) available for gefitinib and Dysphagia

ArticleYear
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment

2014

Other Studies

1 other study(ies) available for gefitinib and Dysphagia

ArticleYear
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.
    BMJ case reports, 2014, Mar-13, Volume: 2014

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines

2014